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ABSTRACT 
Chau, Than Minh. Quality of Life Among Colorectal Cancer Patients During 
Chemotherapy. Unpublished Master of Science in Nursing, University of 
Northern Colorado, 2020. 
 
This study had the general goal of surveying the quality of life (QoL) and related 
factors affecting the QoL of colorectal cancer (CRC) patients participating in cancer 
chemotherapy at University Medical Center (UMC) in Ho Chi Minh City.  The study also 
had the following specific objectives: (a) determining the demographic and clinical 
characteristics of CRC patients and (b) determining health-related quality of life 
(HRQoL) and related factors affecting HRQoL of CRC patients receiving cancer 
chemotherapy. 
A descriptive cross-sectional design was used.  Sixty CRC patients being treated 
at the UMC participated in this study.  The research used the European Organization for 
Research and Treatment of Cancer’s (1995) QLQ-C30 questionnaire to assess the quality 
of life in CRC patients during chemotherapy. 
The results of the study concluded the QoL of CRC patients was impaired by the 
following factors: deficits in emotional and social functioning; physical-related 
restrictions such as fatigue, shortness of breath, insomnia, constipation, and diarrhea; and 
financial difficulties. 
The results of the study improved the knowledge regarding each stage CRC 
patients experienced and their understanding of symptoms and any abnormalities.  
iv 
 
Although more research is needed, this information will be helpful to health professionals 
as they assist patients in maintaining their activities and QoL during chemotherapy. 
Keywords: Quality of Life, Colorectal Patient, Chemotherapy, QLQ-C30. 
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CHAPTER I 
INTRODUCTION 
Background and Significance of Problem 
According to the World Health Organization (WHO, 2018), cancer is the second 
leading cause of death in the world.  In 2018, about 9.6 million people died from cancer, 
which means one out of six people die from cancer.  In addition, 70% of cancer deaths 
occur in low- and middle-income countries (WHO, 2018).  In 2018, with a population of 
96 million people, Vietnam had 165,000 new cases of cancer and about 115,000 people 
died of cancer (WHO, 2019).  From these statistics, it can be seen that cancer has a great 
impact on human health.  
Colorectal cancer (CRC) is a type of cancer that starts in the colon or rectum 
(American Cancer Society [ACS], 2018b).  According to the WHO (2018), about 1.8 
million people around the world suffer from CRC, the third most common cancer after 
lung and breast cancers.  In 2017, there were nearly 135,500 new cases and more than 
50,000 deaths from CRC in the United States (ACS, 2017). According to ACS (2018b) 
estimates, in 2019, there will be about 145,600 new CRC cases and about 51,000 CRC 
deaths in the United States.  In Vietnam, CRC is one of the top five most common 
cancers.  According to WHO (2019) statistics, there were 14,733 new cases and 7,607 
deaths due to CRC in Vietnam in 2018. 
More and more people suffer from cancer diseases in the world and CRC is one of 
them.  The deterioration of health caused by CRC symptoms or the consequences of 
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treatment could lead to physiological, functional, and social damage. As a result, these 
effects could impair a CRC patient’s health-related quality of life (HRQoL; Stefano et al., 
2013).  According to the Centers for Disease Control and Prevention (CDC, 2018), the 
HRQoL concept is based on two levels: individual and community.  On the individual 
level, HRQoL includes physical and mental health perceptions (e.g., energy level, mood) 
and their correlates include health risks and conditions, functional status, social support, 
and socioeconomic status.  On the community level, HRQoL includes community-level 
resources, conditions, policies, and practices that influence a population’s health 
perceptions and functional status.  Health-related quality of life plays an important role in 
assessing the extent of disease, injury, and disability in order to provide preventive 
solutions and to identify risk factors in treatment (CDC, 2018).  For cancer patients, in 
addition to facing fear, they have to endure the complications of the disease and the side 
effects of drugs, which have a negative impact on their HRQoL.  Therefore, appropriate 
interventions should be provided to help them control disease and have a better HRQoL 
(Malathi et al., 2017).  The results of a study conducted in 2016 showed the quality of life 
of colorectal cancer patients was impaired by the following factors: deficits in emotional 
and social functioning; physical-related restrictions such as fatigue, shortness of breath, 
insomnia, constipation, and diarrhea; and financial difficulties (Volker, Henrike, Christa, 
Hartwig, & Hermann, 2016).  
Currently, many cancer treatments have been applied.  However, depending on 
the condition of the patient, the doctor will give specific treatment regimens.  Besides 
patients who use only one treatment, most cases have to combine two to three methods, 
i.e., surgery with chemotherapy or radiation therapy (National Cancer Institute, 2015).  
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Chemotherapy is one of the most popular and effective treatments for cancer patients.  
According to the ACS (2018a), chemotherapy (chemo) is explained simply as the use of 
strong drugs to treat cancer and people began to use this method in the 1950s.  Before 
starting chemotherapy, patients receive information about the effects of the drugs 
including the benefits as well as the side effects.  The main beneficial effects of 
chemotherapy in cancer treatment are to prevent or inhibit cancer cell growth, to kill 
cancer cells, and to reduce symptoms caused by cancer.  On the other hand, 
chemotherapy also brings unwanted side effects to the lives of patients including nausea 
and vomiting, hair loss, bone marrow changes, mouth and skin changes, changes in 
sexual function, fertility problems, and memory changes.  These unintended effects 
depend on many factors such as the type of cancer, where it occurs, stage, health status, 
type of medication, and dose prescribed for each patient (ACS, 2018a).  During 
chemotherapy, HRQoL of patients and caregivers is greatly affected and interventions to 
improve their mental health are necessary (Ioannis et al., 2012).  However, according to 
conclusions from other studies, the effects of the chemotherapy cycle can yield positive 
improvements in patients' HRQoL (Heydarnejad, Dehkordi, & Dehkordi, 2011).  In other 
words, chemotherapy can reduce some of the tumor effects and also promote a patient’s 
more positive attitudes toward the cancer treatment (Harminder, Kamalpreet, Raja, 
Shaminder, & Ritu, 2014).  
Vietnam Context 
University Medical Center (UMC) in Ho Chi Minh City is a public hospital 
established in 1994.  After 25 years, UMC has built a reputation in the field of medical 
examination and health care.  Every year, UMC receives more than two million 
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outpatients.  The Chemotherapy Department (CD) was established and started to operate 
in 2016.  Along with a team of experienced staff in the field of chemotherapy and cancer 
treatment, the CD is a prestigious cancer treatment facility for patients. Currently, the CD 
is an outpatient department with an increasing number of patients being treated with 
chemotherapy every year.  In 2018, the total number of patients receiving treatment was 
25,000.  At the same time, the faculty also coordinated with other clinical departments in 
the diagnosis and treatment of cancer, forming a framework for cancer treatment in the 
spirit of multi-modal treatment.  However, in the process of care and treatment, clinicians 
often paid more attention to symptoms and clinical and subclinical indicators but were 
less concerned about the nutritional, psychological, operability, and chemotherapy 
impacts on the QoL of cancer patients.  Therefore, ensuring the QoL of cancer patients 
needs to be paid more attention.  Additionally, understanding and assessing the HRQoL 
of cancer patients is necessary because cancer patients are often anxious about 
chemotherapy and how it will affect their appearance, digestive system, ability to live, 
current work, and social relationships.  Related issues for cancer patient’s HRQoL have 
not been clarified and have not received needed attention.  For that reason, this study was 
conducted to examine the HRQoL among CRC patients during first stage chemotherapy 
and related factors.  
Purpose of Study 
This study had the general objective of surveying QoL and related factors 
affecting colorectal cancer patients participating in cancer chemotherapy at UMC.  The 
study also had the following specific objectives: determining the demographic and 
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clinical characteristics of CRC patients and determining HRQoL and related factors 
affecting CRC patients receiving chemotherapy. 
Theoretical Framework 
In the nursing discipline, mid-range theories not only play a guiding role but also 
link research and clinical practice.  In 1995, the middle-range theory of unpleasant 
symptoms (TOUS) was developed to understand the experience of symptoms in different 
contexts and multidimensional factors contributing to each symptom (Lenz, Suppe, Gift, 
Pugh, & Milligan, 1995).  In 1997, an updated version of TOUS was published that 
integrated existing knowledge of a range of symptoms and found similarities between 
symptoms to guide research through those similarities (Lenz, Pugh, Milligan, Gift, & 
Suppe, 1997).  In terms of content, TOUS describes the relationship between three main 
components: symptoms patients are experiencing, influencing factors affecting the 
experience of symptoms, and performance outcome or effects of symptoms on patients' 
daily living activities (Lenz et al., 1997).  
Symptoms, the starting point of the theory, represent a change in normal, healthy 
functioning for an individual.  For the purpose of this theory, they are realistic and 
subjective feelings of the patient specifically measured through four characteristics: 
duration, intensity, quality, and distress.  Duration is defined as the time when symptoms 
occur or the frequency of symptoms.  Intensity describes the severity of symptoms. 
Meanwhile, quality is understood as the patient's personal feeling about symptoms that 
are occurring.  Finally, distress is interpreted as the impact of symptoms on the patient’s 
daily life (Lee, Vincent, & Finnegan, 2017).  Although there are patients who experience 
the same symptoms, each person will interpret these four characteristics differently 
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according to their feelings and tolerance levels.  On the other hand, based on the 
description of the theory, symptoms often occur at the same time in clusters instead of 
separately and independently (Lenz et al., 1997). 
The following influencing factors were the second component mentioned in the 
TOUS content: physiologic, psychologic, and situational.  Physiologic factors include 
anatomical, physiological abnormalities or physical impairment, or other genetic and 
disease-related factors.  Psychologic factors include the individual mental state of the 
patient or how they react to the disease.  Lastly, situational factors related to the 
surrounding environment could affect symptom experiences including physical and social 
environments (Lenz & Pugh, 2014). 
Performance outcome is the last component in the TOUS, which is simply defined 
as the result of symptoms’ experiences.  In other words, performance outcome is the level 
to which symptoms have affected the patient's ability to physically, cognitively, and 
socially in everyday life (Lee et al., 2017).  Figure 1 illustrates the original middle-range 
theory of unpleasant symptoms and Figure 2 presents an updated version of the middle-
range theory of unpleasant symptoms (Lenz et al., 1997). 
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Figure 1.  Original diagram of the middle-range theory of unpleasant symptoms (Lenz et 
al., 1997). 
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Figure 2.  Updated version of the middle-range theory of unpleasant symptoms. 
 
Assumptions 
As mentioned, the CD receives and treats about 25,000 people every year.  In the 
course of treatment, aspects related to HRQoL of patients such as nutrition, psychology, 
social relationships, etc., receive less attention.  Although chemotherapy might be 
effective in preventing cancer cell growth, it would help if patients felt more comfortable 
by reducing symptoms of the disease.  Therefore, the assumption of this paper was some 
aspects of HRQoL related to symptoms of the disease would be improved while other 
aspects of HRQoL related to the side effects of chemotherapy drugs would be reduced. 
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CHAPTER II 
LITERATURE REVIEW 
Colorectal Cancer 
Colorectal cancer ranks fourth in the top five most common cancers and the 
second most deadly cancer in the world.  On the other hand, many studies have 
demonstrated that CRC-induced symptoms and side effects during CRC treatment reduce 
patients' HRQoL.  Therefore, it was necessary to evaluate QoL for CRC patients 
throughout the process.  This study was conducted to investigate QoL of CRC patients 
during chemotherapy.  To get an overview of the QoL situation of CRC patients, many 
research documents were synthesized, analyzed, and evaluated.  Using the keywords 
quality of life, colorectal patient, and chemotherapy for searching reliable databases such 
as Medline, PsychInfo, Cumulative Index Nursing Allied Health Literature (CINAHL), 
and Researchgate, a literature review was conducted to understand existing knowledge 
and gaps in QoL management of CRC patients. 
In 2017, a systematic review was conducted by Cabilan and Hines to understand 
the effects of CRC treatment on physical activity, functional status, and QoL.  Regarding 
the method of searching documents, articles and studies searched on databases—
CINAHL, Embase, MEDLINE, OpenGrey and ProQuest—were those written in English, 
and had been implemented since February 2015 until the time of conducting the search. 
As a result, 23 studies met the criteria and were reviewed in terms of relevance, validity, 
and methodological quality.  These studies used the QLQ-C30 questionnaire of the 
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European Organization for Research and Treatment of Cancer (EORTC, 1995) to 
synthesize data. The results of the literature review showed the physical and functional 
status of patients with CRC tended to decrease after six months of treatment.  However, 
after one year of treatment in terms of QoL, the score returned to the baseline level.  In 
the conclusion, Cabilan and Hines commented on the implications for practice and 
research.  In terms of the implications for practice, it would be necessary to have 
appropriate interventions to improve the physical capacity and functional status of CRC 
patients.  When considering the implications for research, the reviewers paid attention to 
the consistency of the results between studies.  In addition, they also suggested a separate 
analysis between colon cancer patients and rectal cancer patients, ostomates, and non-
ostomates patients (Cabilan & Hines, 2017). 
Dunn et al. (2003) conducted a systematic review to describe the general 
knowledge about QoL of CRC patients, reviewed what improvements had been made, 
and identified gaps in the Australian system.  By looking for materials on reliable 
databases such as Medline, PsychInfo, CINAHL and Sociological Abstracts, the authors 
reviewed a total of 41 articles.  In the articles, three main aspects related to QoL of 
patients with CRC were synthesized from the review: QoL definition and measurement, 
QoL prediction, and the relationship between QoL and survival.  However, the results of 
these studies were not consistent, which might have been due to small sample sizes and 
limitations in research methods.  Specifically, the concepts related to QoL in these studies 
were not similar because QoL is a complex, subjective, and difficult concept to quantify. 
Discussing the method of evaluation of QoL, many tools were available for evaluation. 
However, some questionnaires were used for a variety of diseases while others were used 
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for specific diseases.  Therefore, the use of different tools in these studies made it 
difficult to compare results.  Additionally, not all widely used tools met validity and 
reliability requirements as they were still being revised and updated.  On the other hand, 
it was difficult to compare and summarize the content related to the factors identified as 
predictors or correlation of quality of life in patients with CRC, i.e., demographic 
characteristics and illness, time since diagnosis, social support, and physical activity.  
Reason included a limitation in the methodology of the studies and no theoretical basis 
for modeling the predictors of quality.  Finally, there was little evidence to show a 
relationship between QoL and survival (Dunn et al., 2003).  
Studies Using the Quality of Life C30 Questionnaire 
In 2015, Teker, Kemal, and Yucel conducted a study in Turkey with the aim of 
understanding the QoL of CRC patients during chemotherapy.  The authors presented 
three main objectives of the study: evaluate QoL of CRC patients during chemotherapy, 
describe the relevant factors, and assess the relationship between QoL and different 
chemotherapy regimens.  This study was performed at the chemotherapy departments of 
two hospitals with the following sampling criteria: CRC at any stage, Eastern 
Cooperative Oncology Group (ECOG) performance status 0-2, age 18 years or older, and 
received chemotherapy for at least three months.  There were 101 selected study 
participants who were instructed to answer the EORTC (1995) QLQ-C30 questionnaire.  
Based on the tool description in the article, the EORTC QLQ-C30 has a total of 30 
questions corresponding to three scales: global health status, functional, and symptom 
scales. Therefore, the research results were analyzed and discussed mainly based on those 
scales. According to statistical data analysis, demographic characteristics such as 
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education, income, age, and type of chemotherapy affected the global health status scale 
while other characteristics did not.  Additionally, age also affected functional status (p < 
.05).  On the other hand, palliative chemotherapy affected the perception of appetite and 
nausea/vomiting so it had a negative impact on symptom scales by reducing the score of 
this scale (p < .05).  Finally, the authors concluded QoL might be affected by some 
demographic characteristics and different chemotherapy regimens (Teker et al., 2015). 
Another study conducted by Lee et al. in 2016 also explored QoL of cancer 
patients and used the EORTC (1995) QLQ-C30 questionnaire to understand the changes 
related to QoL of patients with colon cancer during chemotherapy treatment in Korea.  In 
the preamble of the study, the authors mentioned the development in oncology surgery 
and chemotherapy helped to increase the survival rate of colon cancer patients.  
Specifically, chemotherapy drugs reduced tumor growth and prevented metastasis.  
However, the side effects of the drugs might affect the patient's QoL so QoL evaluation 
was necessary. Discussing the methodology, 56 post-operative patients who were being 
treated with chemotherapy at Chungbuk National University Hospital were invited to 
participate in the study.  In the study, the EORTC QLQ-C30 questionnaire was used to 
collect data. Survey results demonstrated the two most adverse side effects for patients 
were nausea and peripheral neuropathy.  Specifically, 71.4% of patients were reported to 
have nausea and 55.4% of patients had signs of peripheral neuropathy.  In addition, one 
patient had to end chemotherapy after 11 cycles due to severe effects on peripheral 
neuropathy and another patient manifested an allergy shortly after the infusion.  The 
results of the study also analyzed some of the QoL-related factors and noted that age 
specifically had a significant impact on the global health scale (p = .004), weight gain had 
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a significant impact on the symptom scale (P = 0.033), peripheral neuropathy also 
significantly affected symptoms (p = .042), and delayed chemotherapy had a significant 
effect on the functional scale (p = .041). However, in the conclusions, the authors 
reported the study had shown no significant difference in changing QoL during 
chemotherapy.  Healthcare workers need to have proper awareness regarding reassurance 
and health education for the patient (Lee et al., 2016).  
For the purpose of evaluating QoL of CRC patients during complex treatment, a 
study was conducted on 30 patients diagnosed with CRC at the University Hospital in 
Trnava, Slovakia (Martina, Miroslav, & Lubica, 2017).  Although with the same purpose 
as other studies, this one used a combination of two EORTC (1995) questionnaires: 
EORTC QLQ-C30 and QLQ-CR29 (EORTC, 2006).  A unique aspect of this study was 
the authors analyzed the data within various categories such as type of cancer, 
demographic, and treatment characteristics.  Martina et al. (2017) concluded there was a 
correlation between QoL and type of treatment.  Specifically, in this study, neoadjuvant 
chemoradiotherapy and stoma formation had a more negative impact than radical 
resection with adjuvant chemotherapy (Martina et al., 2017). 
Through the review and analysis of previous studies related to QoL of CRC 
patients, it could be seen the EORTC (1995) QLQ-C30 questionnaire had been applied in 
many studies.  In addition, the EORTC (2006) QLQ-CR29 has also been applied in some 
studies in recent times.  Therefore, further description of these two questionnaires is 
needed. First, both questionnaires were developed by the EORTC (1995, 2006).  The 
QLQ-C30 could be considered the first questionnaire of the EORTC (1995) built to 
assess cancer patients' QoL.  The reliability of the QLQ-C30 has been established as 
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evidenced by the use of QLQ-C30 in many studies with more than 100 translated 
versions in many languages including the Vietnamese version.  In addition to the QLQ-
C30, the EORTC has also developed additional questionnaires to assess patients' QoL 
with different types of cancer including the QLQ-CR38 (Sprangers, Velde, & Aaronson, 
1999), which is used to assess QoL of CRC patients. In the 1990s, QLQ-CR38 was 
translated into many languages and applied in many studies worldwide.  However, during 
this period, many new methods of cancer treatment were developed including 
radiotherapy, new chemotherapy, etc. and they have had a clear effect on reducing 
symptoms caused by cancer.  Therefore, some questions in QLQ-CR38 relating to the 
symptoms of cancer and the side effects of current treatments are no longer appropriate. 
In addition, the QLQ-CR38 was not only judged to be lacking in detail and complexity 
but was also accused of being tested only in the Netherlands and not internationally.  
Therefore, in 2006, the EORTC released an updated version of QLQ-CR38—the 
QLQ-CR29.  This updated process had a total of four phases.  Specifically, in Phase II, a 
temporary module was developed and conducted on 79 CRC patients (from the United 
Kingdom, Germany and France) and 11 healthcare professionals (specialists, nurses, 
surgeon, and oncologist).  After Phase II, 15 items were removed due to duplication 
(seven items) or low relevance (eight items).  After Phases I and II, 29 items were 
synthesized into the QLQ-CR29 and pre-tested on 120 patients in France and Germany 
during Phase III.  Finally, in Phase IV, the QLQ-CR29 proceeded to international field 
testing for reliability, clinical, and psychometric validity.  Specifically, the QLQ-CR29 
was tested on 120 CRC patients in Germany and France.  Test results showed patients 
could understand and accept the questionnaire content.  In addition, according to the 
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comments suggested after the testing, the items for patients with and without stoma had 
been separated while still making sure the items were the same for both groups (Gujral et 
al., 2007).  Additionally, in 2009, Whistance et al. examined the clinical and 
psychometric validity and reliability of the EORTC’s (2006) QLQ-R29 questionnaire in a 
study involving 351 CRC patients of seven different countries (United Kingdom, France, 
Taiwan, Italy, Germany, Spain, and the United States).  The study found correlations 
between the EORTC’s (1995) QLQ-C30 and the QLQ-CR29 were below the coefficient 
of 0.40 for all scales, demonstrating the core questionnaire and supplementary module 
did not overlap in topics (Whistance et al., 2009).  In general, QoL problems of CRC 
patients were of interest and have been studied by many researchers.  Currently, the tool 
has been widely used in the evaluation of QoL of CRC patients and shown to be highly 
reliable.   
In Chapter I, the researcher summarized the content of the theory and physiologic, 
psychologic, and situational factors affecting cancer patients.  This chapter provided a 
literature review that clearly related these factors in other studies.  In addition, the QLQ-
C30 questionnaire was evaluated according to sociodemographic factors and  clinical 
characteristics consistent with the theory framework. 
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CHAPTER III 
METHOD 
Research Design and Sample 
The aim of this study was to evaluate factors related to HRQoL of CRC patients 
undergoing chemotherapy.  To achieve this goal, the study used descriptive cross-
sectional methods.  A convenience sampling method was applied and based on a 
statistical list of patients who had been diagnosed with CRC and were participating in 
chemotherapy at the UMC’s Chemotherapy Department.  In addition, study participants 
were selected according to the following criteria: 
• CRC patients were receiving chemotherapy at UMC's Chemotherapy 
department. 
• The patient agreed to participate in the study after hearing the explanation of 
the study’s purpose. 
• The patient had the ability to perceive and read Vietnamese. 
• The patient was healthy enough to participate. 
• The patient had no mental illness. 
Exclusion criteria in the sample collection process resulted in the removal of the 
following participants: 
• The patient stopped participating in the study; 
• The patient was having health concerns and refused participation. 
• The patient did not follow the instructions in the survey questionnaire; 
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• The patient was incapable of understanding or unable to answer (old, 
hearing impaired, or suffering from mental illnesses). 
For patients who met the sampling criteria, the researcher explained the purpose of 
the study, how to participate in the study, and the benefits/risks involved in the study.  If 
the patient agreed after the explanation, the patient signed the Vietnamese version of the 
University of Northern Colorado’s (UNC) informed consent form (see Appendix A). 
After that, the patient answered the questions in the survey before joining chemotherapy 
during the day (see Appendix B).  The purpose of the timing of the survey was to reduce 
the impact of answering questions because patients treated after chemotherapy are often 
tired of the side effects of the drugs.  While the patient answered the questionnaire, the 
researcher was next to the patient to answer any questions.  
In this study, the sample size was expected to be 60 patients.  According to 2018 
statistics, the Chemotherapy Department had about 630 colon cancer patients and 350 
rectal cancer patients participating in chemotherapy.  With the cancer treatment regimen, 
they undergo six to eight phases; each phase is two to three weeks apart with clinical tests  
to ensure eligibility for chemotherapy.  In six months of 2019, the number of patients 
with colorectal cancer participating in chemotherapy increased on average 10-12 people 
per day.  Therefore, during a relatively short time period, this study enrolled a sample of 
60 people. 
To conduct the survey, the questionnaire in this study was the EORTC’s (1995) 
QLQ-C30.  In particular, the QLQ-C30 was developed to assess the quality of life of 
cancer patients.  It has been translated and validated into more than 100 languages 
including Vietnamese and is used every year in more than 5,000 studies worldwide.  The 
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completed questionnaire in this study had a total of 30 questions, which was tested by at 
least two experts before the patient was tested and was adjusted to ensure the relevance to 
the research subjects (if any).  The questionnaire in Vietnamese was printed on paper and 
distributed to participants.  
Ethical Considerations 
Regarding medical ethics, this study was conducted with the approval of UNC’s 
Institutional Review Board (see Appendix C) and the Scientific Council of UMC where 
the study was conducted (see Appendix D).  Additionally, the researcher explained that 
participation was voluntary and refusal to participate in the research would not affect the 
quality of treatment and care of participants.  Furthermore, the information provided by 
the patient was for research purposes only and would be kept completely confidential.  
Information requested by the questionnaire was not offensive and did not affect the 
patient mentally or physically. 
Data Analysis 
Data were entered and processed by SPSS software 20.0 and presented by 
frequency, percentage (quantitative variable), and average value ± standard deviation. 
Data analysis involved descriptive statistics related to the variables.  In addition, 
Cronbach’s alpha was determined for the instrument.  The p value of .05 was set for 
statistical significance.  Researchers must ensure the clarity and accuracy in the 
information and instructions for answering questions for study participants.  Incomplete 
survey forms regarding study variables were removed and not used. 
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This chapter presented important steps to carry out a study.  Sections included the 
research design, criteria of sample, population, instrument, collection, research ethics, 
and analysis of the data. 
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CHAPTER IV 
RESULTS 
Introduction 
 
To answer the research questions, responses to the EORTC (1995) QLQC30 were 
analyzed.  The demographic and clinical characteristics of the participants were described 
and related to the TOUS (Lenz et al., 1997) theory of the patient's experience of 
symptoms.  Results of the QLQC30 questionnaire are presented as the mean value of the 
global health status, functional scales, social function, the cognitive function, financial 
difficulties, and symptom scales.  Data were collected from August 18 to 29, 2019 and 60 
consecutive patients with CRC undergoing chemotherapy were included.  All patients 
were diagnosed and treated at University Medical Center.   
Patient Characteristics 
The mean age among patients was 57.38±11.07 (see Table 1); the maximal age 
was 82-years-old and the minimal age was 32-years-old (see Figure 3). The mean age for 
males was higher than the female mean age but no significant difference was found 
(58.38 and 55.78, respectively; p = .382 > .05).   
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Table 1 
Mean Age Among Patients 
 
Gender Minimal Age Maximal Age M ± SD p-value 
Male 32 82 58.38±10.88 p = 0.382 
Female 36 71 55.78±11.41 
Total 32 82 57.38±11.07  
 
 
 
Figure 3.  Gender distribution. 
 
Other baseline characteristics among the research subjects included education 
level and insurance status (see Table 2).  Forty percent of research participants had 
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completed high school; 23.3% had attended college or university, and 36.7% had only a 
primary-secondary school education.  All patients interviewed had health insurance.    
 
Table 2  
Background Characteristics Among the Subjects 
 
Characteristics n % 
Level of Education    
    Primary-Secondary School 22 36.7 
    High School  24 40.0 
    College/University 14 23.3 
Health Insurance    
    Yes  60 100 
    No  0 0 
N = 60 
 
Clinical Characteristics 
The clinical characteristics of patients are shown in Table 3.  More than half of 
the patients (75%) had colon cancer and the remaining (25%) had rectal cancer.  The 
majority of the patients (83.3%) were receiving Xelox protocol and the remaining 
patients were receiving Xeliri and others (11.7% and 5%, respectively).  Almost all 
patients (16.7%) had undergone Phase 4 and Phase 5 of therapeutic processes.  The 
prevalence of ostomates and non-ostomates patients was 21.7% and 78.3%, respectively.  
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Table 3  
Clinical Data for Study Subjects 
 
Characteristics n % 
Diagnosis   
    Colon cancer 45 75.0 
    Rectal cancer 15 25.0 
   
Protocol   
    Xelox 50 83.3 
    Xeliri   7 11.7 
    Others   3   5.0 
   
Phase   
    1   3   5.0 
    2   9 15.0 
    3   8 13.3 
    4 10 16.7 
    5 10 16.7 
    6   3   5.0 
    7   8 13.3 
    8   4   6.7 
    >8   5   8.3 
   
Stoma   
    Yes 13 21.7 
    No  47 78.3 
N = 60 
 
 
Results of the Quality of Life Questionnaire 
The mean value of the global health status/QoL was 69.17±19.90 points standard 
deviations (SD).  Within the functional scales, social function (SF) was rated lowest with 
a mean score of 80.83±22.51 points, whereas the cognitive function (CF) was rated 
highest with a mean of 88.06±14.09 points.  Reported financial difficulties (FI) had a 
mean value of 30.0±28.59 points; the lowest was diarrhea with a mean value of 
10.56±17.88 points.  Figure 4 presents a visual representation of the survey results. 
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Figure 4.  Results of the survey (European Organization for Research and Treatment of 
Cancer, Quality of Life Questionnaire, version 3.0). Indicated values are the mean of all 
pooled patients (N = 60). QoL: quality of life, PF2: physical functioning, RF2: role 
functioning, EF2: emotional functioning, CF2: cognitive functioning, SF2: social 
functioning, FA: fatigue, NV: nausea and vomiting, PA: pain, DY: dyspnea, SL: 
insomnia, AP: appetite loss, CO: constipation, DI: diarrhea, FI: financial difficulties. 
 
 
Quality of Life in Colorectal Cancer Patients 
The patients were evaluated according to age and were divided into two groups 
(<60 years and >60 years).  The age of 60 was used as cut off according to the WHO’s 
(2020) definition of an older person (see Table 4). There was no significant difference in 
global health status and functional scales by age (67 and 75, respectively; p = .516) but 
financial difficulties were lower in older than in younger patients (20 and 40, 
respectively; p < .05).  
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Table 4  
Quality of Life Survey Scores by Age Groups 
 
Global Health Status  Age < 60 years Age 60+ years  p-value  
QoL (M±SD)  
Median (Q1/Q3) 
67.24±21.35 
66.67 (62.5/83.3) 
70.97±18.62 
75.0 (66.67/83.33) 
0.516 
Functional Scales 
Physical functioning (PF2)  88.74±13.81 
93.33 (80.00/100) 
86.45±12.94 
86.67 (80.0/100) 
0.415 
Role functioning (RF2)  81.03±20.28 
83.33 (66.67/100) 
83.87±16.93 
83.33 (66.67/100) 
0.737 
Cognitive functioning (CF)  86.21±11.84 
83.33 (83.33/100) 
89.78±15.91 
100.00 (83.33/100) 
0.089 
Emotional functioning (EF)  83.62±16.74 
91.67 (66.67/100) 
88.44±17.57 
91.67 (83.33/100) 
0.175 
Social functioning (SF) 80.46±21.40 
83.33 (66.67/100) 
81.18±23.86 
83.33 (66.67/100) 
0.734 
Symptom Scales/Items 
Fatigue (FA)  25.29±22.20 
22.22 (5.56/38.89) 
22.94±17.67 
22.22 (11.11/33.33)  
0.780 
Nausea and vomiting (NV)  13.22±24.14 
0 (0/16.67) 
10.22±16.49 
0 (0/16.67)  
0.937 
Pain (PA)  18.97±19.27 
16.67n(0/33.33) 
16.13±22.15 
0 (0/33.33)  
0.315 
Dyspnea (DY) 18.39±26.10 
0 (0/33.33) 
10.75±21.75 
0 (0/0)  
0.156 
Insomnia (SL)  14.94±26.10 
0 (0/33.33) 
25.81±25.40 
33.33 (0/33.33) 
0.051 
Appetite loss (AP)  24.14±29.41 
33.33 (0/33.33) 
26.88±29.08 
33.33(0/33.33)  
0.659 
Constipation (CO)  8.05±17.03 
0 (0/0) 
17.20±22.56 
0 (0/33.33)  
0.075 
Diarrhea (DI)  8.05±17.03 
0 (0/0) 
12.90±18.61 
0 (0/33.33)  
0.227 
Financial difficulties (FI)  40.23±25.79 
33.33(33.33/66.67)  
20.430±28.12 
0 (0/33.33)         
0.003* 
*Mann Whitney test 
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The mean score for global health status among males was significantly high 
compared to females (73.65 and 61.96, respectively; p < .05).  In contrast, the mean 
scores for nausea and vomiting (NV) and constipation (CO) in male patients were lower 
than for females (7.66 and 18.12, respectively; 9.01 and 18.84, respectively) with p < .05. 
There was no significant difference in functional and other symptom scales (see Table 5).  
Patients were also divided into groups according to the level of education.  The 
results showed no difference in global health status but there were some differences in the 
functional and symptom scales (see Table 6).  For instance, lower scores were obtained 
from primary-secondary level patients with respect to role functioning (RF2), emotional 
functioning (EF), and social functioning (SF) than from higher education groups (p < 
.05).  The fatigue (FA) and financial difficulties (FI) scores were worse in the lower 
educational level group than in the others (p < .05). 
Patients who were receiving different protocols (Xelox, Xeliri, or Others) were 
compared on QoL functional and symptom scores.  Table 7 depicts the results of this 
analysis.  No statistical difference was found in scores among the patients who were 
experiencing different protocols (p > .05). 
Finally, with respect to the comparison between ostomates (n = 13) and non-
ostomates patients (n = 47), there was no significant difference in global health status and 
functional scales (see Table 8).  However, for the symptom scales, the NV was worse in 
the non-ostomates patient group than in the ostomates patient group (p < .05). 
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Table 5 
Association Between Quality of Life Survey Scores and Gender 
 
Global Health Status  Male  Female  p-value  
QoL (M+-SD)  
Median (Q1/Q3) 
73.65±20.08 
83.33 (66.67/83.33) 
61.96±17.74  
66.67 (50.0/75.0) 
0.004* 
                                 Functional Scales  
Physical functioning (PF2)  88.47±13.67 
93.33 (80.0/100) 
86.09±12.86 
86.67 (80.0/100) 
0.372 
Role functioning (RF2)  82.88±19.84 
83.33 (66.67/100)  
81.88±16.6 
83.33 (66.67/100) 
0.613 
Cognitive functioning (CF)  90.09±13.87 
100 (83.33/100) 
84.78±14.14 
83.33 (83.33/100) 
0.095 
Emotional functioning (EF)  88.06±16.14 
91.67 (83.33/100) 
82.97±18.72 
91.67 (66.67/100) 
0.223 
Social functioning (SF) 81.08±21.58 
83.33 (66.67/100) 
80.43±24.44 
83.33 (66.67/100) 
0.981 
                                     Symptom Scales/Items 
Fatigue (FA)  21.62±20.45 
83.33 (66.67/100)  
28.02±18.61 
22.22 
(11.11/44.44) 
0.163 
Nausea and vomiting (NV)  7.66±18.67 
0 (0/8.33) 
18.12±21.85 
16.67 (0/33.33) 
0.019* 
Pain (PA)  17.57±21.14 
16.67 (0/33.33) 
17.39±20.4 
16.67 (0/33.33) 
0.942 
Dyspnea (DY) 9.91±19.03 
0 (0/16.67)  
21.74±29.49 
0 (0/33.33) 
0.093 
Insomnia (SL)  18.02±24.34 
0 (0/33.33)  
24.64±28.81 
0 (0/66.67) 
0.416 
Appetite loss (AP)  22.52±28.39 
0 (0/33.33)  
30.43±30.01 
33.33 (0/66.67) 
0.267 
Constipation (CO)  9.01±18.67 
0 (0/0)  
18.84±22.08 
0 (0/33.33) 
0.043* 
Diarrhea (DI)  9.01±16.94 
0 (0/16.67)  
13.04±19.43 
0 (0/33.33)  
0.384 
Financial difficulties (FI)  
 
27.93±29.93 
33.33 (0/33.33)  
33.33±26.59 
33.33 (0/66.67) 
0.357 
*Mann Whitney test 
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Table 6 
Quality of Life Survey Scores Distributed by Educational Levels 
 
Global Health Status Primary- 
Secondary 
School 
High School Colleges/ 
University 
p-value 
QoL (M+-SD)  61.90±18.98 70.83±19.35 71.97±20.82 0.155 
                             Functional Scales  
Physical functioning (PF2)  86.19±11.54 
 
88.61±15.66 87.27±11.98 0.462 
Role functioning (RF2)   67.86±17.86 83.33±17.72 90.91±14.30 0.001 
Cognitive functioning (CF)  83.33±13.07 
 
87.50±14.12 91.67±14.32 
 
0.080 
Emotional functioning (EF)  76.19±18.16 87.50±16.11 90.91±15.83 
 
0.017 
Social functioning (SF) 69.05±19.46 
 
81.94±20.21 87.12±24.63 
 
0.013 
                                  Symptom Scales/Items 
Fatigue (FA)  35.71±19.58 21.76±19.79 19.19±17.877 
 
0.040 
Nausea and vomiting (NV)  14.29±21.54 14.58±25.69 6.82±11.10 
 
0.662 
Pain (PA)  23.81±21.40 
 
15.28±21.38 15.91±19.57 
 
0.276 
Dyspnea (DY) 26.19±35.03 13.89±19.45 7.58±17.61 
 
0.164 
Insomnia (SL)  21.43±24.83 20.83±29.18 19.70±24.47 0.952 
Appetite loss (AP)  30.95±35.72 
 
27.78±30.56 19.70±22.20 0.667 
Constipation (CO)  21.43±24.83 
 
9.72±18.33 10.61±18.93 0.211 
Diarrhea (DI)  16.67±25.32 9.72±15.48 7.58±14.30 0.569 
Financial difficulties (FI) 47.62±31.25 27.78±27.22 21.21±24.22 0.031 
*Kruskal-Wallis test   
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Table 7 
Association Between Quality of Life Survey Scores and Protocols 
 
Global Health Status Xelox Xeliri Others p-value 
QoL (M+-SD)  68.50±21.12 72.62±10.45 72.22±19.25 0.936 
                                  Functional Scales  
Physical functioning (PF2)  88.93±10.83 81.90±23.64 77.78±19.25 0.560 
Role functioning (RF2)  82.33±17.63 76.19±25.2 100±0.0 0.161 
Cognitive functioning (CF)  88.67±13.65 85.71±11.50 83.33±28.87 0.708 
Emotional functioning (EF)  86.50±16.95 83.33±20.97 86.11±17.35 0.992 
Social functioning (SF) 80.00±23.57 83.33±16.667 88.89±19.25 0811 
                               Symptom Scales/Items 
Fatigue (FA)  24.00±18.83 28.57±28.59 14.81±16.97 0.715 
Nausea and vomiting (NV)  10.00±17.17 28.57±35.64 0.0±0.0 0.118 
Pain (PA)  16.67±20.20 19.05±24.40 27.78±25.46 0.655 
Dyspnea (DY) 15.33±24.48 14.29±26.23 0.0±0.0 0.488 
Insomnia (SL)  20.00±24.28 28.57±40.50 11.11±19.25 0.820 
Appetite loss (AP)  24.67±28.42 33.33±38.49 22.22±19.25 0.875 
Constipation (CO)  12.67±20.08 9.52±16.27 22.22±38.49 0.900 
Diarrhea (DI)  11.33±18.58 4.76±12.60 11.11±19.25 0.668 
Financial difficulties (FI)  28.67±29.36 38.10±23.00 33.33±33.33 0.578 
*Kruskal-Wallis test 
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Table 8 
Quality of Life Survey Scores in Ostomate and Non-Ostomate Patients 
Global Health Status Ostomates 
Patients 
Non-Ostomates 
Patients 
p-value 
QoL (M+-SD)  73.08±25.04 68.09±18.42 0.122 
                                 Functional Scales  
Physical functioning (PF2)  87.18±11.37 87.66±13.90 0.657 
Role functioning (RF2)  82.05±24.019 82.62±17.01 0.762 
Cognitive functioning (CF)  88.46±14.25 87.94±14.20 0.930 
Emotional functioning (EF)  89.74±13.24 85.11±18.14 0.395 
Social functioning (SF) 82.05±18.59 80.50±23.65 0.992 
                          Symptom Scales/Items 
Fatigue (FA) 22.22±14.34 24.59±21.23 0.949 
Nausea and vomiting (NV)  2.56±9.25 14.18±21.97 0.028 
Pain (PA)  16.67±19.25 17.73±21.25 0.962 
Dyspnea (DY) 7.69±14.618 16.31±25.89 0.352 
Insomnia (SL)  10.26±16.01 23.40±27.73 0.141 
Appetite loss (AP)  15.38±22.01 28.37±0.28 0.168 
Constipation (CO)  7.69±19.97 14.18±20.55 0.202 
Diarrhea (DI)  5.13±12.52 12.06±18.94 0.230 
Financial difficulties (FI)  28.21±26.69 30.50±29.35 0.879 
*Mann Whitney test 
 
In summary, Chapter IV provided the results of a detailed analysis of the quality 
of life of colorectal cancer patients participating in this study.  The results of the EORTC 
(1995) QLQC30 questionnaire were presented as the means of all pooled patients: quality 
of life, physical functioning, role functioning, emotional functioning, cognitive 
functioning, social functioning, fatigue, nausea and vomiting, pain, dyspnea, insomnia, 
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appetite loss, constipation, diarrhea, and financial aspects.  The results of the analysis 
indicated significant differences in several areas of QoL in colorectal cancer patients, 
which are discussed more specifically in Chapter V.   
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CHAPTER V 
DISCUSSION 
Introduction 
Although gastrointestinal tumors represent a major healthcare problem 
worldwide, data for the QoL for patients suffering from this kind of cancer are rare, 
especially data deriving from routine clinical practice (Benoist, Tournigand, Andre, & de 
Gramont, 2011).  According to Testa and Simonson (1996), QoL has become more 
important in healthcare practice and clinical research.  Despite the importance of QoL 
evaluations, standardized methods have not applied in most oncology centers in Vietnam. 
Traditionally, the effect of treatment has been evaluated by the frequency or intensity of a 
given symptom measured by physicians.  In this study, a single, well-established and 
reliable assessment tool--the EORTC (1995) QLQ-C30 (version 3)—was used instead of 
several different specific questionnaires for patients to describe quality of life of CRC 
patients being treated at UMC’s oncology center in Vietnam.  
General Characteristics 
In general, for the colorectal cancer patients at UMC, the mean value of the global 
health status/QoL was 69.17 ± 19.90 points.  Within the functional scales, social function 
was rated lowest with a mean score of 80.83 ± 22.51 points, whereas the cognitive 
function was rated highest with a mean of 88.06 ± 14.09 points.  The most notable 
symptom was financial difficulties with a mean value of 30.0 ± 28.59 points and the 
lowest was diarrhea with a mean value of 10.56 ± 17.88 points.  
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There were some differences in this study compared with the research results of 
Teker et al. (2015), which was a study conducted to assess the QoL in colorectal cancer 
patients during chemotherapy in the era of monoclonal antibody therapies at the 
Department of Medical Oncology in Samsun, Turkey.  The mean value of the global 
health status was 56.0 ± 26.6 points compared with 69.17 in this study.  Within the 
functional scales, physical function was rated lowest (versus social function in the current 
study) whereas the cognitive function was rated highest, which was similar to this study. 
The most distinctive symptom was fatigue and the lowest was dyspnea. These differences 
might have been due to differences in the subjects, place, and type of chemotherapy 
regimen. 
Correlation of the Factors 
In comparing QoL in colorectal cancer patients between elderly and younger 
patients, the two groups showed similar QoL in global health status and functional scales; 
however, elders reported better outcomes regarding financial difficulties.  Care for the 
elderly, their needs for financial assistance, and health services are critical problems.  In 
Vietnam, there is increasing financial support from the state health system for the elderly 
by providing more support for medical services for older people and their families.  On 
July 1, 2010, Law number 39/2009/QH12 was adopted (Vietnam National Assembly, 
2009); the law defines the rights and responsibilities of elderly people, responsibilities of 
institutions, organizations, families and individuals in relation to the elderly, as well as a 
foundation for the care and financial support of the elderly (Ngoc, Baryshevab, & 
Lyubov, 2016).  The Ministry of Health plans to publish a circular "Standardization of 
Geriatric Departments at Hospitals” to meet the growing demand for protecting the health 
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of the elderly in accordance with Law No. 39/2009/QH12 (Vietnam National Assembly, 
2009).   
This study also indicated a variety of significant differences in the QoL in 
colorectal cancer patients by gender.  The mean score of global health status for males 
was significantly higher than for females (73.65 and 61.96, respectively; p < .05).  The 
mean scores for nausea and vomiting and constipation in male patients were significantly 
lower (p < .05) than for females (7.66 and 18.12, respectively; 9.01 and 18.84, 
respectively).  A possible explanation of gender differences in QoL was women might 
exaggerate their health conditions more than men or women might have a higher rate of 
self-perceived health regarding general health and symptoms/signs, which might explain 
why women had a lower level QoL.  Also, they are referred to physicians and health 
centers more than men.  The symptoms and signs related to postmenopausal 
comorbidities in women might also partially explain the gender differences in HRQoL.  
Although no relationship was demonstrated between education and QoL scores in 
several studies, a variation was observed in the current study at different levels of 
education.  Role functioning, emotional functioning, and social functioning scores were 
higher in university graduate patients than in others.  Fatigue and financial difficulties 
scores were found to be significantly lower (better and higher scores represented a greater 
degree of symptoms) than those of patients with lower educational levels.  This might be 
because patients develop certain social and other skills and become more functional as 
their level of education rises.  Fatigue, financial difficulties, and limitations in role 
functioning might be related to emotional problems.  
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In the current study, there was no difference among different chemotherapy 
protocols of CRC patients (p > .05), which meant different chemotherapy protocols did 
not negatively affect QoL (Wintner et al., 2013).  Chemotherapy might have actually 
maintained the QoL. When deciding on further chemotherapy protocols, health 
professionals usually use the ECOG performance status and ask a few brief questions to 
understand the tolerability potential of the patient.  Actually, applying a QoL 
questionnaire to every new patient would provide more detailed information about the 
patient.   
This was the first reported study about the effects of different chemotherapy 
protocols on QoL in patients with CRC in Vietnam.  Conditions affecting the QoL could 
be related to stoma (Teker et al., 2015).  The nausea/vomiting scores were lower in 
ostomate patients than in others.  Patients with a stoma were usually more aware of the 
effects of treatment and might use antiemetics more regularly. 
Limitations 
Convenience sampling at a single hospital in Vietnam limited the generalization 
of this study.  The time collecting the sample was also short.  Since some patients might 
have been experiencing adverse effects from their treatment, the concentration needed to 
answer the questionnaire might have reduced the accuracy of the results.  
Recommendations 
According to the results, the following recommendations are made related to 
improving the quality of life for CRC patients undergoing treatment: 
1. For each stage of colorectal cancer, patients have different influencing 
factors.  A mental health plan and health education are needed at every 
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stage.  This is necessary to prepare them for the changes in their health 
condition.  Patient knowledge would help them with self-care and to identify 
abnormal signs related to chemotherapy.  Assessing this information would 
be helpful to medical staff to monitor the side effects of the drug.  In 
addition, patients could learn to detect abnormal signs early and reduce 
those symptoms.  Patients could control daily activities and work better 
when they understand their health status. 
2. Nurses need to pay more attention to the mental and economic status of 
patients to reduce anxiety during treatment.  The cost of treatment should be 
disclosed and explained before the patient participates in treatment.  The 
cost of each protocol at each stage is different and patients are attempting to 
control their finances and prepare for the regimen.  Health providers in 
Vietnam should encourage patients to use health insurance, especially 
government insurance that provides high benefits for a low cost. 
Application of Theoretical Framework 
In the theory of unpleasant symptoms, three categories of factors were identified 
as influencing the occurrence, intensity, timing, distress level, and quality of symptoms: 
physiologic, psychologic, and situational factors (Lenz et al., 1997).  In the Vietnam 
context, this study drew a picture about real experiences and patient issues.  The results 
showed colorectal cancer patients did not demonstrate differences in clinical 
characteristics among protocols of chemotherapy.  The data analyzed 60 colorectal cancer 
patients to find the influence of factors utilizing the EORTC’s (1995) QLQ-C30 tool. 
Factors such as economy, educational level, gender, and morale affect the quality of life 
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of patients.  Young people have a lack of economic stability compared to older people. 
Women are more resistant to side effects of drugs.  Patients with knowledge are better 
able to control symtoms.  Using health insurance brings benefits and convenience during 
chemotherapy.  Patients are more informed about hospital costs for protocols.  Clinical 
characteristics when undergoing certain protocols have been improved.  The quality of 
life of colorectal cancer patients is increased based on both small and necessary factors.  
Improved awareness of patients about ways to manage themselves and their symptoms 
helps them to feel more confident about their life. 
Conclusion 
The aim of this study was to discover factors that affect colorectal cancer patients, 
which could improve their quality of life.  Research into the QoL of CRC patients was 
important in the world and in Vietnam.  A review of literature related to studies of QoL 
for this patient population was documented and compared.  In addition, the tool used to 
gather the data was the EORTC’s (1995) QLQ-C30 questionnaire—a reliable and valid 
questionnaire that has been used in many studies.  This study was based on the TOUS 
theoretical framework that dealt with patient experiences and included three factors: 
physiologic, psychologic, situational.  The level of influence depended on the stage of the 
disease and the health status of each patient.  The analysis showed most clinical 
symptoms did not vary significantly among the treatment regimens.  The results also 
demonstrated the financial and emotional/mental factors of patients must be considered.  
Colorectal cancer patients in Vietnam are often concerned with clinical symptoms and 
social and mental needs; however, there has been little regard for these concerns.  
Vietnamese patients also do not understand the problems they experience during 
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chemotherapy because they have little knowledge of their treatment and disease 
characteristics and depend on the guidance of the physician and a nurse.  Different 
patients experience different symptoms and problems.  Therefore, they need a detailed 
care plan that is appropriate for each stage of cancer.  
This study was conducted at the UMC Hospital, which is a modern hospital in 
Vietnam.  Thus, there is a need to gather a larger sample in various settings to uncover 
many other aspects and factors that influence colorectal cancer patients.  Research results 
could help nurses understand their patients as well as improve their quality of life.  When 
care is more evidence based, colorectal cancer patients in Vietnam will also receive better 
care and attention.    
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INFORMED CONSENT FOR PARTICIPATION  
IN HUMAN SUBJECTS RESEARCH 
 
Project Title: Quality of life among colorectal cancer patients during chemotherapy 
Student Researcher: Chau Than Minh 
Research Advisor: Jeanette McNeill DrPH, RN, ANEF, CNE, School of nursing 
Purpose: The purpose of this project is a survey the quality of life and related factors 
affecting the quality of life of colorectal cancer patients participating in cancer 
chemotherapy for the first time at UMC hospital 
Objective: This project plans to  
− Determining the relation between demographic clinical characteristics and the 
quality of life scores among colorectal cancer patients at Chemotherapy 
Department, UMC hospital; 
− Determining the mean score of health-related quality of life and related factors 
among colorectal cancer patients with C30 questionnaire. 
All responses will be kept confidential and anonymous.  All questionnaires will be 
scanned into a password protected computer and then “shredded” (permanently 
destroyed). All study data and information will then be kept on a thumb drive in a locked 
drawer in a locked cabinet. There are no anticipated risks by participation in this survey. 
If you complete the survey, it will be assumed that you have communicated consent for 
your participation. You may keep this form for future reference.  
 
If you agree to participate in this study you will be asked to complete the attached 30 
question survey.  It should take you 5-10 minutes to complete. 
 
Participation is voluntary. You may decide not to participate in this study and if you 
begin participation you may still decide to stop and withdraw at any time. Your decision 
will be respected and will not result in loss of benefits to which you are otherwise 
entitled.  
 
Having read the above and having had an opportunity to ask any questions in this 
research. A copy of this form will be given to you to retain for future reference. If you 
have any concerns about your selection or treatment as a research participant, please 
contact the Office of Research, Kepner Hall, University of Northern Colorado Greeley, 
CO 80639; 970-351-1910. 
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Please give this informed consent and the completed questionnaire to the researcher (the 
one who gave you the form). 
 
Committee Contact information:  
Student Researcher: Chau Than Minh – MSN Student 
Email: than0389@bears.unco.edu or chau.tm@umc.edu.vn 
 
Research Advisor: Jeanette McNeill, DrPH, RN, ANEF, CNE 
Professor, University of Northern Colorado, School of nursing, Greeley, CO 
Email: jeanette.mcneill@unco.edu 
Phone: 970-351-1704  
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THÔNG TIN ĐỒNG Ý DÀNH CHO ĐỐI TƯỢNG THAM GIA NGHIÊN CỨU 
Tên đề tài: Chất lượng cuộc sống của người bệnh ung thư đại trực tràng trong quá trình hoá trị 
liệu 
Nghiên cứu sinh: Thân Minh Châu 
Giảng viên hướng dẫn: Jeanette McNeill, Tiến sĩ Điều dưỡng, Đại học Northern Colorado  
Mục đích: Mục đích của dự án này là khảo sát chất lượng cuộc sống và các yếu tố liên quan ảnh 
hưởng đến chất lượng cuộc sống của người bệnh ung thư đại trực tràng tham gia hóa trị ung thư 
lần đầu tiên tại bệnh viện Đại học Y Dược thành phố Hồ Chí Minh (UMC). 
Mục tiêu:  
− Xác định mối quan hệ giữa các đặc điểm lâm sàng nhân khẩu học và chất lượng cuộc 
sống giữa các người bệnh ung thư đại trực tràng tại Khoa Hóa trị ung thư, bệnh viện 
UMC; 
− Xác định điểm trung bình của chất lượng cuộc sống liên quan đến sức khỏe và các yếu tố 
liên quan ở người bệnh ung thư đại trực tràng với bảng câu hỏi QLQ-C30. 
Việc tham gia là tự nguyện. Bạn có thể quyết định không tham gia nghiên cứu này và nếu bạn bắt 
đầu tham gia, bạn vẫn có thể dừng và rời đi vào bất cứ thời điểm nào. Sự quyết định của bạn luôn 
được tôn trọng và không ảnh hưởng đến quyền lợi mà bạn đang có. 
Vui lòng đọc và có thể hỏi bất kỳ câu hỏi nào. 
 
Nếu bạn đồng ý tham gia nghiên cứu bạn sẽ trả lời 30 câu hỏi khảo sát. Thời gian hoàn thành 
khảo sát từ 5-10 phút. 
 
Một bản sao của giấy này sẽ được gửi bạn giữ tham khảo cho tương lai. Nếu bạn có bất kỳ mối 
quan tâm cho việc chọn lựa hay điều trị như một người tham gia nghiên cứu, vui lòng liên hệ Cơ 
Quan Nghiên Cứu, Kepner Hall, Trường Đại Học Northern Colorado Greeley, CO 80639; 970-
351-1910. 
 
Vui lòng cho thông tin đồng ý này và hoàn thành bảng câu hỏi nghiên cứu (người đưa bạn mẫu 
thông tin này) 
 
Thông tin liên lạc của hội đồng:  
Nghiên cứu sinh: Thân Minh Châu, Sinh viên lớp Thạc sĩ Điều dưỡng 
Email: than0389@bears.unco.edu hoặc chau.tm@umc.edu.vn  
 
Cố vấn nghiên cứu: Jeanett McNeill, Tiến sĩ Điều dưỡng, Đại học Northern Colorado 
Email: jeanett.mcneill@unco.edu 
Điện thoại: 970-351-1704 
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QLQC30 QUESTIONNAIRE 
We are interested in some things about you and your health. Please answer all of the 
questions yourself by circling the number that best applies to you. There are no "right" or 
"wrong" answers. The information that you provide will remain strictly confidential. 
 
A. Question 
Rating 
Not 
at 
all 
A 
little 
Quite 
a bit 
Very 
much 
A1. Do you have any trouble doing strenuous activities, 
like carrying a heavy shopping bag or a suitcase? 
1 2 3 4 
A2. Do you have any trouble taking a long walk? 1 2 3 4 
A3. Do you have any trouble taking a short walk outside 
of the house? 
1 2 3 4 
A4. Do you need to stay in bed or a chair during the day? 1 2 3 4 
A5. Do you need help with eating, dressing, washing 
yourself or using the toilet? 
1 2 3 4 
During the past week: 
A6. Were you limited in doing either your work or other 
daily activities? 
1 2 3 4 
A7. Were you limited in pursuing your hobbies or other 
leisure time activities? 
1 2 3 4 
A8. Were you short of breath? 1 2 3 4 
A9. Have you had pain? 1 2 3 4 
A10. Did you need to rest? 1 2 3 4 
A11. Have you had trouble sleeping? 1 2 3 4 
A12. Have you felt weak? 1 2 3 4 
A13. Have you lacked appetite? 1 2 3 4 
A14. Have you felt nauseated? 1 2 3 4 
A15. Have you vomited? 1 2 3 4 
A16. Have you been constipated? 1 2 3 4 
A17. Have you had diarrhea? 1 2 3 4 
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A18. Were you tired? 1 2 3 4 
A19. Did pain interfere with your daily activities? 1 2 3 4 
A20. Have you had difficulty in concentrating on things, 
like reading a newspaper or watching television? 
1 2 3 4 
A21. Did you feel tense? 1 2 3 4 
A22. Did you worry? 1 2 3 4 
A23. Did you feel irritable? 1 2 3 4 
A24. Did you feel depressed? 1 2 3 4 
A25. Have you had difficulty remembering things? 1 2 3 4 
A26. Has your physical condition or medical treatment 
interfered with your family life? 
1 2 3 4 
A27. Has your physical condition or medical treatment 
interfered with your social activities? 
1 2 3 4 
A28. Has your physical condition or medical treatment 
caused you financial difficulties? 
1 2 3 4 
 
For the following questions please circle the number between 1 and 7 that best 
applies to you 
A29. How would you rate your overall health during the past week? 
1 2 3 4 5 6 7 
Very poor      Excellent 
A30. How would you rate your overall quality of life during the past week? 
1 2 3 4 5 6 7 
Very poor      Excellent 
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B.  General Information 
B1. 
Gender 
 Ma
le 
 Female B2. Year of birth:  ..............................  
B3. Education: 
Primary-Secondary School      High School      Colleges/University  
Post-graduate 
B4. 
Diagnose:  
Colon cancer Rectal cancer 
B5. 
Protocol: 
 Xelox  Xeliri  Others 
B6. Phase: 1 2 3 4 5 6 7 8  > 8 
B7. Stoma Yes No 
B8. 
Insurance 
Yes No 
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QLQC30 BỘ CÂU HỎI NGHIÊN CỨU 
 
Chúng tôi quan quan tâm đến một số thông tin về bạn và sức khỏe của bạn. Xin vui lòng 
trả lời các câu hỏi bởi chính bạn bằng cách khoanh tròn các con số thích hợp nhất đối với 
trường hợp của bạn. Không có câu trả lời “đúng” hay “sai”. Thông tin mà bạn cung cấp 
sẽ được giữ kín hoàn toàn. 
A. Câu hỏi 
Thang điểm 
Không 
có 
Ít Nhiều 
Rất 
nhiều 
A1. Bạn có thấy khó khăn khi thực hiện những công 
việc gắng sức, ví dụ như xách một túi đồ nặng hay một 
vali? 
1 2 3 4 
A2. Bạn có thấy khó khăn khi đi bộ một khoảng dài? 1 2 3 4 
A3. Bạn có thấy khó khăn khi đi bộ một khoảng ngắn 
bên ngoài nhà mình? 
1 2 3 4 
A4. Bạn có cần nằm nghỉ trên giường hay trên ghế suốt 
ngày? 
1 2 3 4 
A5. Bạn có cần giúp đỡ khi ăn, mặc, tắm rửa hay đi vệ 
sinh? 
1 2 3 4 
Trong tuần vừa qua: 
A6. Bạn đã có bị hạn chế thực hiện trong việc làm của 
bạn hoặc trong các công việc hàng ngày khác? 
1 2 3 4 
A7. Bạn đã có bị hạn chế trong theo đuổi các sở thích 
của bạn hay trong các hoạt động giải trí khác? 
1 2 3 4 
A8. Bạn đã có bị thở nhanh không? 1 2 3 4 
A9. Bạn đã bị đau gì không? 1 2 3 4 
A10. Bạn đã cần phải nghỉ ngơi không? 1 2 3 4 
A11. Bạn có bị mất ngủ? 1 2 3 4 
A12. Bạn có cảm thấy yếu sức? 1 2 3 4 
A13. Bạn có bị ăn mất ngon? 1 2 3 4 
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A14. Bạn có cảm giác buồn nôn? 1 2 3 4 
A15. Bạn có bị nôn? 1 2 3 4 
A16. Bạn có bị bón? 1 2 3 4 
A17. Bạn có bị tiêu chảy? 1 2 3 4 
A18. Bạn đã có bị mệt không? 1 2 3 4 
A19. Cơn đau có cản trở sinh hoạt hàng ngày của bạn? 1 2 3 4 
A20. Bạn đã có bị khó khăn khi tập trung vào công việc 
gì, như khi đọc báo hay xem truyền hình? 
1 2 3 4 
A21. Bạn đã có cảm thấy căng thẳng? 1 2 3 4 
A22. Bạn đã có lo lắng? 1 2 3 4 
A23. Bạn đã có cảm thấy dễ bực tức? 1 2 3 4 
A24. Bạn đã có cảm thấy buồn chán? 1 2 3 4 
A25. Bạn đã gặp khó khăn khi phải nhớ lại một sự 
việc? 
1 2 3 4 
A26. Tình trạng thể lực của bạn hoặc việc điều trị bệnh 
gây cản trở cuộc sống gia đình của bạn? 
1 2 3 4 
A27. Tình trạng thể lực của bạn hoặc việc điều trị bệnh 
gây cản trở cho các hoạt động xã hội của bạn? 
1 2 3 4 
A28. Tình trạng thể lực của bạn hoặc việc điều trị bệnh 
tạo ra khó khăn tài chánh của bạn? 
1 2 3 4 
 
Đối với những câu hỏi sau, vui lòng khoanh tròn con số trong khoảng từ số 1 đến số 
7 mà phù hợp nhất đối với bạn. 
A29. Bạn tự đánh giá như thể nào về sức khỏe tổng quát của bạn trong tuần qua? 
1 2 3 4 5 6 7 
Rất kém      Tuyệt hảo 
A30. Bạn tự đánh giá như thế nào về chất lượng cuộc sống tổng quát của bạn trong 
tuần qua? 
1 2 3 4 5 6 7 
Rất kém      Tuyệt hảo 
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B. Thông tin cá nhân 
B1. Giới tính  Nam  Nữ 
B2. Năm sinh: 
 ..............................................................  
B3. Trình độ học vấn: 
Tiểu học -THCS THPT              Cao đẳng/Đại học              Sau Đại học    
B4. Chẩn đoán:  Ung thư đại tràng Ung thư trực tràng 
B5. Phác đồ  
điều trị hiện tại:  
 Xelox  Xeliri  Khác 
B6. Đợt hóa trị: 1 2 3 4 5 6 7 8  > 8 
B7. Hậu môn 
nhân tạo 
Có Không 
B8. Bảo hiểm y tế Có Không 
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